DK3567035T3 - N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer - Google Patents
N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer Download PDFInfo
- Publication number
- DK3567035T3 DK3567035T3 DK19167943.0T DK19167943T DK3567035T3 DK 3567035 T3 DK3567035 T3 DK 3567035T3 DK 19167943 T DK19167943 T DK 19167943T DK 3567035 T3 DK3567035 T3 DK 3567035T3
- Authority
- DK
- Denmark
- Prior art keywords
- dioxo
- cancer
- substituted
- treatment
- azoline compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91125807P | 2007-04-11 | 2007-04-11 | |
| EP16165912.3A EP3088397B1 (en) | 2007-04-11 | 2008-04-11 | Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3567035T3 true DK3567035T3 (da) | 2022-09-05 |
Family
ID=39939984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19167943.0T DK3567035T3 (da) | 2007-04-11 | 2008-04-11 | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer |
| DK08829410.3T DK2152692T3 (en) | 2007-04-11 | 2008-04-11 | EXTERNAL anti-cancer activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08829410.3T DK2152692T3 (en) | 2007-04-11 | 2008-04-11 | EXTERNAL anti-cancer activity |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8084454B2 (enExample) |
| EP (4) | EP4074704A1 (enExample) |
| JP (2) | JP5635396B2 (enExample) |
| KR (1) | KR101475311B1 (enExample) |
| CN (2) | CN101720323A (enExample) |
| AU (1) | AU2008294410B2 (enExample) |
| BR (2) | BR122022005149B1 (enExample) |
| CA (4) | CA3030510C (enExample) |
| DK (2) | DK3567035T3 (enExample) |
| ES (3) | ES2732230T3 (enExample) |
| HU (2) | HUE029370T2 (enExample) |
| IL (4) | IL309201A (enExample) |
| MX (3) | MX374896B (enExample) |
| NZ (1) | NZ580237A (enExample) |
| RU (1) | RU2482111C2 (enExample) |
| WO (1) | WO2009031040A2 (enExample) |
| ZA (1) | ZA200906960B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3567035T3 (da) * | 2007-04-11 | 2022-09-05 | Canbas Co Ltd | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer |
| EP2304436A1 (en) | 2008-07-10 | 2011-04-06 | Nodality, Inc. | Methods for diagnosis, prognosis and treatment |
| EP3620154A1 (en) * | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| US20100215644A1 (en) * | 2009-02-25 | 2010-08-26 | Nodality, Inc. A Delaware Corporation | Analysis of nodes in cellular pathways |
| CN104744215B (zh) | 2010-03-03 | 2019-03-15 | 尼昂克技术公司 | 包含单萜的药物组合物 |
| US9499461B2 (en) | 2010-08-27 | 2016-11-22 | Neonc Technologies, Inc. | Pharmaceutical compositions comprising POH derivatives |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| ES3056006T3 (en) | 2010-12-17 | 2026-02-17 | Univ Southern California | Methods and devices for using isoperillyl alcohol |
| WO2013020024A2 (en) * | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| US9814693B2 (en) | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| ES2563861T3 (es) | 2012-06-14 | 2016-03-16 | Daiichi Sankyo Company, Limited | Derivado de piperidinilpirazolopiridina |
| EP2951174B1 (en) * | 2013-01-30 | 2017-04-26 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| US9540462B2 (en) | 2014-12-05 | 2017-01-10 | Massachusetts Institute Of Technology | Catechol-rich polymers from N-substituted maleimides |
| SI3250550T1 (sl) * | 2015-01-26 | 2023-08-31 | Ottawa Hospital Research Institute | Sestave in metode za senzibilizacijo virusov |
| WO2016130800A2 (en) | 2015-02-12 | 2016-08-18 | Neonc Technologies Inc. | Pharmaceutical compositions comprising perillyl alcohol derivatives |
| TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
| USD915100S1 (en) | 2016-03-31 | 2021-04-06 | Ocean 22, Llc | Spooled item holding device |
| USD801721S1 (en) | 2016-03-31 | 2017-11-07 | Patricia Grayson Briden | Spooled item holding device |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| JP2021512165A (ja) | 2018-01-29 | 2021-05-13 | コグノス・セラピューティクス・インコーポレイテッド | ボルテゾミブの腫瘍内送達 |
| MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
| CA3087925A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| JP7325425B2 (ja) | 2018-02-08 | 2023-08-14 | ネオンク テクノロジーズ インク． | 血液脳関門を透過性にする方法 |
| EP4153599B1 (en) | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| WO2021233884A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| EP4415700A4 (en) * | 2021-10-15 | 2025-12-24 | Univ Missouri | P1B TYPE ATPASES INHIBITORS |
| CN114425054A (zh) * | 2022-01-20 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途 |
| CN120247782B (zh) * | 2025-06-04 | 2025-08-19 | 北京颖泰嘉和生物科技股份有限公司 | 氟吡菌酰胺类化合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5564557A (en) * | 1978-11-08 | 1980-05-15 | Mitsui Toatsu Chem Inc | Diphenyl ether compound and herbicide containing the same |
| IL81307A0 (en) * | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| US5635966A (en) * | 1994-01-11 | 1997-06-03 | Hewlett-Packard Company | Edge feed ink delivery thermal inkjet printhead structure and method of fabrication |
| JPH07224032A (ja) | 1994-02-09 | 1995-08-22 | Mitsui Petrochem Ind Ltd | Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤 |
| JPH07244032A (ja) * | 1994-03-01 | 1995-09-19 | Ishikawajima Harima Heavy Ind Co Ltd | 溶接部検査装置 |
| AU726058B2 (en) * | 1995-09-01 | 2000-10-26 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
| US6205557B1 (en) | 1998-06-09 | 2001-03-20 | At&T Corp. | Redundant call processing |
| AU2093400A (en) * | 1998-11-24 | 2000-06-13 | Basf Aktiengesellschaft | Fungicides containing pyrrolidones as their active agents |
| DE60019318T2 (de) | 1999-09-22 | 2006-03-09 | Canbas Co., Ltd., Numazu | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe |
| DE50104105D1 (de) * | 2000-02-26 | 2004-11-18 | Basf Ag | Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen |
| JP2002318434A (ja) * | 2001-04-23 | 2002-10-31 | Konica Corp | ハロゲン化銀写真感光材料、処理方法、および画像形成方法 |
| FR2826653B1 (fr) * | 2001-06-29 | 2005-10-14 | Servier Lab | Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2487388C (en) | 2002-06-06 | 2011-05-10 | Canbas Co., Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| WO2005024755A2 (en) * | 2002-12-31 | 2005-03-17 | Deciphera Pharmaceuticals, Llc. | Medicaments for the treatment of neurodegenerative disorders or diabetes |
| US7572816B2 (en) * | 2003-08-01 | 2009-08-11 | Auspex Pharmaceuticals, Inc. | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
| KR101149124B1 (ko) * | 2004-03-10 | 2012-05-25 | 가부시끼가이샤 구레하 | 아민계 염기성 화합물과 그의 용도 |
| CA2559866A1 (en) * | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| EP1851203A2 (en) | 2005-02-08 | 2007-11-07 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| CA2619706A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| CN101321747A (zh) * | 2005-11-01 | 2008-12-10 | 詹森药业有限公司 | 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类 |
| US7994205B2 (en) * | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
| US20080221103A1 (en) | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| DK3567035T3 (da) | 2007-04-11 | 2022-09-05 | Canbas Co Ltd | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer |
-
2008
- 2008-04-11 DK DK19167943.0T patent/DK3567035T3/da active
- 2008-04-11 RU RU2009141619/04A patent/RU2482111C2/ru active
- 2008-04-11 NZ NZ580237A patent/NZ580237A/en unknown
- 2008-04-11 CA CA3030510A patent/CA3030510C/en active Active
- 2008-04-11 HU HUE08829410A patent/HUE029370T2/hu unknown
- 2008-04-11 BR BR122022005149-9A patent/BR122022005149B1/pt active IP Right Grant
- 2008-04-11 CA CA2913840A patent/CA2913840C/en active Active
- 2008-04-11 ES ES16165912T patent/ES2732230T3/es active Active
- 2008-04-11 CA CA2684037A patent/CA2684037C/en active Active
- 2008-04-11 US US12/082,643 patent/US8084454B2/en active Active
- 2008-04-11 ES ES08829410.3T patent/ES2594704T3/es active Active
- 2008-04-11 MX MX2015016591A patent/MX374896B/es unknown
- 2008-04-11 ES ES19167943T patent/ES2927954T3/es active Active
- 2008-04-11 MX MX2020009403A patent/MX391154B/es unknown
- 2008-04-11 JP JP2010502609A patent/JP5635396B2/ja active Active
- 2008-04-11 IL IL309201A patent/IL309201A/en unknown
- 2008-04-11 KR KR1020097023566A patent/KR101475311B1/ko active Active
- 2008-04-11 WO PCT/IB2008/003036 patent/WO2009031040A2/en not_active Ceased
- 2008-04-11 HU HUE19167943A patent/HUE059861T2/hu unknown
- 2008-04-11 BR BRPI0810911-7A patent/BRPI0810911B1/pt active IP Right Grant
- 2008-04-11 EP EP22176177.8A patent/EP4074704A1/en not_active Withdrawn
- 2008-04-11 CN CN200880019414A patent/CN101720323A/zh active Pending
- 2008-04-11 IL IL289165A patent/IL289165B2/en unknown
- 2008-04-11 AU AU2008294410A patent/AU2008294410B2/en active Active
- 2008-04-11 CA CA3188320A patent/CA3188320A1/en active Pending
- 2008-04-11 CN CN201510578313.XA patent/CN105175394B/zh active Active
- 2008-04-11 EP EP19167943.0A patent/EP3567035B1/en active Active
- 2008-04-11 EP EP08829410.3A patent/EP2152692B9/en active Active
- 2008-04-11 MX MX2009011025A patent/MX2009011025A/es unknown
- 2008-04-11 EP EP16165912.3A patent/EP3088397B1/en active Active
- 2008-04-11 DK DK08829410.3T patent/DK2152692T3/en active
-
2009
- 2009-10-06 ZA ZA2009/06960A patent/ZA200906960B/en unknown
- 2009-10-11 IL IL201380A patent/IL201380A0/en active IP Right Grant
-
2010
- 2010-11-19 US US12/950,297 patent/US8415357B2/en active Active
-
2013
- 2013-08-28 JP JP2013176324A patent/JP2014012706A/ja not_active Withdrawn
-
2015
- 2015-12-02 IL IL242883A patent/IL242883B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020006I1 (lt) | GDF gaudyklės, skirtos naudoti anemijos gydymui | |
| HUE059861T2 (hu) | N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra | |
| DK2205257T3 (da) | Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer | |
| DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| DK2195015T3 (da) | Sammensætning til behandling af prostatacancer | |
| PL3354276T3 (pl) | Kompozycje do leczenia zapalenia przewodu pokarmowego | |
| DK2154971T3 (da) | Synergistisk farmaceutisk kombination til behandling af cancer | |
| SMP200900085B (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative. | |
| DK2100614T3 (da) | Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer | |
| DK2139483T3 (da) | Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
| DK3424932T3 (da) | Bronophthalider til terapeutisk anvendelse | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| IL197217B (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
| DK1960370T3 (da) | Pyridazinonderivater til tumorbehandling | |
| ZA200906129B (en) | Compounds for the treatment of hepatitis c | |
| DK1928438T3 (da) | Anvendelse af ibudilast til behandling af stofafhængighed | |
| DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK2117525T3 (da) | Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte | |
| DK2101805T3 (da) | Integrinligander til anvendelse i behandling af cancer | |
| DK2209784T3 (da) | Forbindelser til behandling af hepatitis C |